Oestrogens as modulators of neuronal signalosomes and brain lipid homeostasis related to protection against neurodegeneration

Journal of Neuroendocrinology

Volumn 25, Issue 11, 2013, Pages 1104-1115

  Marin, R ^a   Casanas V ^a   Perez J A ^a   Fabelo, N ^a   Fernandez, C E ^a   Diaz, M ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Cholesterol; Docosahexaenoic acid; Lipid raft signalling; Neurodegeneration; Neuroprotection; Oestrogen; Oestrogen receptor

Indexed keywords

AMYLOID BETA PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DOCOSAHEXAENOIC ACID; ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; LIPID; NEURONAL SIGNALOSOME; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; CELL MEMBRANE; DEGENERATIVE DISEASE; HOMEOSTASIS; HORMONE BINDING; HUMAN; HYPOTHESIS; LIPID BRAIN LEVEL; LIPID COMPOSITION; LIPID RAFT; MICROENVIRONMENT; MOLECULAR INTERACTION; NERVE CELL MEMBRANE; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; BRAIN; METABOLISM; PHYSIOLOGY;

BRAIN; HOMEOSTASIS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84886703025     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12068     Document Type: Review

References (155)

1. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of oestrogen: basic mechanisms and clinical implications. Steroids 2007; 72: 381-405.
2. Petrovska S, Dejanova B, Jurisic V. Estrogens: mechanisms of neuroprotective effects. J Physiol Biochem 2012; 68: 455-460.
3. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav 2012; 63: 301-307.
4. Al SS, Sánchez MG, Bourque M, Morissette M, Dluzen D, Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J Neuroendocrinol 2012; 24: 48-61.
5. Liu R, Yang SH. Window of opportunity: estrogen as a treatment for ischemic stroke. Brain Res 2013; 1514: 83-90.
6. Henderson VW. Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006; 138: 1031-1039.
7. Henderson VW. Oestrogens and dementia. Novartis Found Symp 2000; 230: 254-265.
8. Resnick SM, Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomised clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials 2004; 1: 440-450.
9. Valen-Sendstad A, Engedal K, Stray-Pedersen B, Strobel C, Barnett L, Meyer N, Nurminemi M, ADACT Study Group. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomised, doubleblind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry 2010; 18: 11-20.
10. Zandi PP, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002; 288: 2123-2129.
11. Heys M, Jiang C, Cheng KK, Zhang W, Au Yeung SL, Lam TH, Leung GM, Schooling CM. Life long endogenous estrogen exposure and later adulthood cognitive function in a population of naturally postmenopausal women from Southern China: the Guangzhou Biobank Cohort Study. Psychoneuroendocrinology 2011; 36: 864-873.
12. Maki PM. Minireview: effects of different HT formulations on cognition. Endocrinology 2012; 153: 3564-3570.
13. Brown CM, Suzuki S, Jelks KA, Wise PM. Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin Reprod Med 2009; 27: 240-249.
14. Barron AM, Pike CJ. Sex hormones, aging, and Alzheimer's disease. Front Biosci (Elite Ed) 2012; 4: 976-997.
15. Marin R, Guerra B, Alonso R, Ramirez CM, Diaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res 2005; 2: 287-301.
16. Raz L, Khan MM, Mahesh VB, Vadlamudi RK, Brann DW. Rapid estrogen signaling in the brain. Neurosignals 2008; 16: 140-153.
17. Marin R, Ramírez CM, González M, González-Muñoz E, Zorzano A, Camps M, Alonso R, Díaz M. Voltage-dependent anion channel (VDAC) participates in amyloid beta-induced toxicity and interacts with plasma membrane estrogen receptor alpha in septal and hippocampal neurons. Mol Membr Biol 2007; 24: 148-160.
18. Marin R, Díaz M, Alonso R, Sanz A, Arévalo MA, Garcia-Segura LM. Role of estrogen receptor alpha in membrane-initiated signaling in neural cells: interaction with IGF-1 receptor. J Steroid Biochem Mol Biol 2009; 114: 2-7.
19. Martin V, Fabelo N, Santpere G, Puig B, Marín R, Ferrer I, Díaz M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010; 19: 489-502.
20. Fabelo N, Martín V, Santpere G, Marín R, Torrent L, Ferrer I, Díaz M. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med 2011; 17: 1107-1118.
21. Fabelo N, Martin V, González C, Alonso A, Diaz M. Effects of oestradiol on brain lipid class and Fatty Acid composition: comparison between pregnant and ovariectomised oestradiol-treated rats. J Neuroendocrinol 2012a; 24: 292-309.
22. Milner TA, McEwen BS, Hayashi S, Li CJ, Reagan LP, Alves SE. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol 2001; 429: 355-371.
23. Pedram A, Razandi M, Sainson RC, Kim JK, Hughes CC, Levin ER. A conserved mechanism for steroid receptor translocation to the plasma membrane. J Biol Chem 2007; 282: 22278-22288.
24. Simpkins JW, Singh M, Brock C, Etgen AM. Neuroprotection and estrogen receptors. Neuroendocrinology 2012; 96: 119-130.
25. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 2001; 98: 1952-1957.
26. Hoffman GE, Merchenthaler I, Zup SL. Neuroprotection by ovarian hormones in animal models of neurological disease. Endocrine 2006; 29: 217-231.
27. Cordey M, Pike CJ. Neuroprotective properties of selective estrogen receptor agonists in cultured neurons. Brain Res 2005; 1045: 217-223.
28. Marin R, Ramírez C, Morales A, González M, Alonso R, Díaz M. Modulation of Abeta-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids 2008; 73: 992-996.
29. Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, Dun NJ. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol 2007; 193: 311-321.
30. Toran-Allerand CD. Estrogen and the brain: beyond ER-alpha, ER-beta, and 17beta-estradiol. Ann NY Acad Sci 2005; 1052: 136-144.
31. Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly ES Jr, Nethrapalli IS, Tinnikov AA. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 2002; 22: 8391-8401.
32. Levin ER. Plasma membrane estrogen receptors. Trends Endocrinol Metab 2009; 20: 477-482.
33. Gingerich S, Kim GL, Chalmers JA, Koletar MM, Wang X, Wang Y, Belsham DD. Estrogen receptor α and G-protein coupled receptor 30 mediate the neuroprotective effects of 17β-estradiol in novel murine hippocampal cell models. Neuroscience 2010; 170: 54-66.
34. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med 2013; 19: 197-209.
35. Marin R. Signalosomes in the brain: relevance in the development of certain neuropathologies such as Alzheimer's disease. Front Physiol 2011; 2: 23-28.
36. Micevych P, Dominguez R. Membrane estradiol signaling in the brain. Front Neuroendocrinol 2009; 30: 315-327.
37. Huang GZ, Woolley CS. Estradiol acutely suppresses inhibition in the hippocampus through a sex-specific endocannabinoid and mGluR-dependent mechanism. Neuron 2012; 74: 801-808.
38. Sohrabji F, Selvamani A, Balden R. Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke. Horm Behav 2013; 63: 222-230.
39. Wehling M, Lösel R. Non-genomic steroid hormone effects: membrane or intracellular receptors? J Steroid Biochem Mol Biol 2006; 102: 180-183.
40. Srivastava DP, Waters EM, Mermelstein PG, Kramár EA, Shors TJ, Liu F. Rapid estrogen signaling in the brain: implications for the fine-tuning of neuronal circuitry. J Neurosci 2011; 31: 16056-16063.
41. Mani SK, Mermelstein PG, Tetel MJ, Anesetti G. Convergence of multiple mechanisms of steroid hormone action. Horm Metab Res 2012; 44: 569-576.
42. Toran-Allerand CD. Estrogen and the brain: beyond ER-alpha and ER-beta. Exp Gerontol 2004; 39: 1579-1586.
43. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
44. Correia SC, Santos RX, Cardoso S, Carvalho C, Santos MS, Oliveira CR, Moreira PI. Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease? Curr Aging Sci 2010; 3: 113-126.
45. Marin R, Guerra B, Morales A, Díaz M, Alonso R. An estrogen membrane receptor participates in estradiol actions for the prevention of amyloid beta-peptide1-40-induced toxicity in septal-derived cholinergic SN56 cells. J Neurochem 2003; 85: 1180-1189.
46. Marin R, Ramírez CM, González M, Alonso R, Díaz M. Alternative estrogen receptors homologous to classical receptor alpha in murine neural tissues. Neurosci Lett 2006; 395: 7-11.
47. Guerra B, Díaz M, Alonso R, Marin R. Plasma membrane oestrogen receptor mediates neuroprotection against beta-amyloid toxicity through activation of Raf-1/MEK/ERK cascade in septal-derived cholinergic SN56 cells. J Neurochem 2004; 91: 99-109.
48. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 2007; 14: 2848-2864.
49. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010; 327: 46-50.
50. Schengrund CL. Lipid rafts: keys to neurodegeneration. Brain Res Bull 2010; 82: 7-17.
51. Marin R, Marrero-Alonso J, Fernandez C, Cury D, Diaz M. Estrogen receptors in lipid raft signalling complexes for neuroprotection. Front Biosci (Elite Ed) 2012; 4: 1420-1433.
52. Deecher DC, Swiggard P, Frail DE, O'Connor LT. Characterization of a membrane-associated estrogen receptor in a rat hypothalamic cell line (D12). Endocrine 2003; 22: 211-223.
53. Ramirez CM, González M, Díaz M, Alonso R, Ferrer I, Santpere G, Puig B, Meyer G, Marin R. VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer's disease. Mol Cell Neurosci 2009; 42: 172-183.
54. Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 2007; 27: 9941-9950.
55. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 2005; 16: 231-237.
56. Christensen A, Micevych P. CAV1 siRNA reduces membrane estrogen receptor-α levels and attenuates sexual receptivity. Endocrinology 2012; 153: 3872-3877.
57. La Rosa P, Pesiri V, Leclercq G, Marino M, Acconcia F. Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity. Mol Endocrinol 2012; 26: 762-774.
58. Marquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 2006; 246: 91-100.
59. Reineri S, Bertoni A, Sanna E, Baldassarri S, Sarasso C, Zanfa M, Canobbio I, Torti M, Sinigaglia F. Membrane lipid rafts coordinate estrogen-dependent signaling in human platelets. Biochim Biophys Acta 2007; 1773: 273-278.
60. Chung TH, Wang SM, Liang JY, Yang SH, Wu JC. The interaction of estrogen receptor alpha and caveolin-3 regulates connexin43 phosphorylation in metabolic inhibition-treated rat cardiomyocytes. Int J Biochem Cell Biol 2009; 41: 2323-2333.
61. Meitzen J, Mermelstein PG. Estrogen receptors stimulate brain region specific metabotropic glutamate receptors to rapidly initiate signal transduction pathways. J Chem Neuroanat 2011; 42: 236-241.
62. Hicks DA, Nalivaeva NN, Turner AJ. Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. Front Physiol 2012; 3: 189-194.
63. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem 2012; 120(Suppl. 1): 9-21.
64. Akanda N, Tofighi R, Brask J, Tamm C, Elinder F, Ceccatelli S. Voltage-dependent anion channels (VDAC) in the plasma membrane play a critical role in apoptosis in differentiated hippocampal neurons but not in neural stem cells. Cell Cycle 2008; 7: 3225-3234.
65. De Pinto V, Messina A, Lane DJ, Lawen A. Voltage-dependent anion-selective channel (VDAC) in the plasma membrane. FEBS Lett 2010; 584: 1793-1799.
66. Park E, Lee GJ, Choi S, Choi SK, Chae SJ, Kang SW, Pak YK, Park HK. The role of glutamate release on voltage-dependent anion channels (VDAC)-mediated apoptosis in an eleven vessel occlusion model in rats. PLoS ONE 2010; 5: e15192.
67. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009; 41: 425-431.
68. Cuadrado-Tejedor M, Vilariño M, Cabodevilla F, Del Río J, Frechilla D, Pérez-Mediavilla A. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β. J Alzheimers Dis 2011; 23: 195-206.
69. Manczak M, Reddy PH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 2012; 21: 5131-5146.
70. Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2013; 1832: 67-75.
71. Hur JY, Teranishi Y, Kihara T, Yamamoto NG, Inoue M, Hosia W, Hashimoto M, Winblad B, Frykman S, Tjernberg LO. Identification of novel γ-secretase-associated proteins in detergent-resistant membranes from brain. J Biol Chem 2012; 287: 11991-12005.
72. Shoshan-Barmatz V, Ben-Hail D. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion 2012; 12: 24-34.
73. Yoo BC, Fountoulakis M, Cairns N, Lubec G. Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. Electrophoresis 2001; 22: 172-179.
74. Herrera JL, Diaz M, Hernández-Fernaud JR, Salido E, Alonso R, Fernández C, Morales A, Marin R. Voltage-dependent anion channel as a resident protein of lipid rafts: post-transductional regulation by estrogens and involvement in neuronal preservation against Alzheimer's disease. J Neurochem 2011; 116: 820-827.
75. Diaz M, Bahamonde MI, Lock H, Muñoz FJ, Hardy SP, Posas F, Valverde MA. Okadaic acid-sensitive activation of Maxi Cl(-) channels by triphenylethylene antioestrogens in C1300 mouse neuroblastoma cells. J Physiol 2001; 536: 79-88.
76. Le Mellay V, Troppmair J, Benz R, Rapp UR. Negative regulation of mitochondrial VDAC channels by C-Raf kinase. BMC Cell Biol 2002; 3: 14.
77. Herrera JL, Fernandez C, Diaz M, Cury D, Marin R. Estradiol and tamoxifen differentially regulate a plasmalemmal voltage-dependent anion channel involved in amyloid-beta induced neurotoxicity. Steroids 2011; 76: 840-844.
78. Distler AM, Kerner J, Hoppel CL. Post-translational modifications of rat liver mitochondrial outer membrane proteins identified by mass spectrometry. Biochim Biophys Acta 2007; 1774: 628-636.
79. Bera AK, Ghosh S. Dual mode of gating of voltage-dependent anion channel as revealed by phosphorylation. J Struct Biol 2001; 135: 67-72.
80. Valverde MA, Hardy SP, Díaz M. Activation of Maxi Cl(-) channels by antiestrogens and phenothiazines in NIH3T3 fibroblasts. Steroids 2002; 67: 439-445.
81. Marin R. Lipid rafts play a crucial role in protein interactions and intracelular signaling involved in neuronal preservation against Alzheimer's disease. In: Jelinek R, ed. Lipids and Cellular Membranes in Amyloid Diseases. Verlag & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany: Wiley-VCH, 2011: 159-175.
82. Garcia-Segura LM, Sanz A, Mendez P. Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology 2006; 84: 275-279.
83. Garcia-Segura LM, Arévalo MA, Azcoitia I. Interactions of estradiol and insulin-like growth factor-I signalling in the nervous system: new advances. Prog Brain Res 2010; 181: 251-272.
84. Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 2010; 11: 688-699.
85. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008; 47: 6991-7000.
86. Sato I, Obata Y, Kasahara K, Nakayama Y, Fukumoto Y, Yamasaki T, Yokoyama KK, Saito T, Yamaguchi N. Differential trafficking of Src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain. J Cell Sci 2009; 122: 965-975.
87. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 2006; 23: 111-122.
88. Williamson R, Sutherland C. Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains. Curr Alzheimer Res 2011; 8: 213-221.
89. Rushworth JV, Hooper NM. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis 2010; 2011: 603052.
90. Zampagni M, Evangelisti E, Cascella R, Liguri G, Becatti M, Pensalfini A, Uberti D, Cenini G, Memo M, Bagnoli S, Nacmias B, Sorbi S, Cecchi C. Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med (Berl) 2010; 88: 597-608.
91. Hashimoto M, Takenouchi T, Rockenstein E, Masliah E. Alpha-Synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem 2003; 85: 1468-1479.
92. Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 2007; 46: 1868-1877.
93. Fabelo N, Martín V, Marín R, Santpere G, Aso E, Ferrer I, Díaz M. Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease. J Neuropathol Exp Neurol 2012b; 71: 868-881.
94. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005; 45: 1-28.
95. Plourde M, Fortier M, Vandal M, Tremblay-Mercier J, Freemantle E, Bégin M, Pifferi F, Cunnane SC. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 301-308.
96. Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, Zhang H, Wang L, Kim TW, Duff KE, Wenk MR, Arancio O, Di Paolo G. Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. J Neurosci 2010; 30: 16419-16428.
97. Han X. Lipid alterations in the earliest clinically recognisable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2005; 2: 65-77.
98. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998; 55: 326-335.
99. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001; 103: 373-383.
100. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1-27.
101. Chapkin RS, Wang N, Fan YY, Lupton JR, Prior IA. Docosahexaenoic acid alters the size and distribution of cell surface microdomains. Biochim Biophys Acta 2008; 1778: 466-471.
102. Diaz ML, Fabelo N, Marin R. Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice. Front Physiol 2012; 3: 454-469.
103. Gross RW, Jenkins CM, Yang J, Mancuso DJ, Han X. Functional lipidomics: the roles of specialised lipids and lipid-protein interactions in modulating neuronal function. Prostaglandins Other Lipid Mediat 2005; 77: 52-64.
104. Lee AG. Lipid-protein interactions. Biochem Soc Trans 2011; 39: 761-766.
105. Luoma JI, Boulware MI, Mermelstein PG. Caveolin proteins and estrogen signaling in the brain. Mol Cell Endocrinol 2008; 290: 8-13.
106. Marin R, Marrero-Alonso J, Fernandez C, Cury D, Diaz M. Membrane-initiated signaling of estrogen related to neuroprotection. 'Social networks' are required. Horm Mol Biol Clin Invest 2011; 7: 393-401.
107. Mermelstein PG. Membrane-localised oestrogen receptor alpha and beta influence neuronal activity through activation of metabotropic glutamate receptors. Neuroendocrinol 2009; 21: 257-262.
108. Yavin E, Glozman S, Green P. Docosahexaenoic acid sources for the developing brain during intrauterine life. Nutr Health 2001; 15: 219-224.
109. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr 2007; 137: 855-859.
110. Karr JE, Alexander JE, Winningham RG. Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan: a review. Nutr Neurosci 2011; 14: 216-225.
111. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001; 42: 1257-1265.
112. Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000; 35: 105-111.
113. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24: 806-815.
114. Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem Res 1996; 21: 463-470.
115. Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 2005; 29: 190-201.
116. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001; 12: 105-112.
117. Fünfschilling U, Saher G, Xiao L, Möbius W, Nave KA. Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci 2007; 8: 1.
118. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 2003; 60: 1158-1171.
119. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001; 294: 1354-1357.
120. Uelmen PJ, Oka K, Sullivan M, Chang CC, Chang TY, Chan L. Tissue-specific expression and cholesterol regulation of acylcoenzyme A: cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro. J Biol Chem 1995; 270: 26192-26201.
121. Shibuya K, Takata N, Hojo Y, Furukawa A, Yasumatsu N, Kimoto T, Enami T, Suzuki K, Tanabe N, Ishii H, Mukai H, Takahashi T, Hattori TA, Kawato S. Hippocampal cytochrome P450s synthesise brain neurosteroids which are paracrine neuromodulators of synaptic signal transduction. Biochim Biophys Acta 2003; 1619: 301-316.
122. Grösgen S, Grimm MO, Friess P, Hartmann T. Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta 2010; 1801: 966-974.
123. Söderberg M, Edlund C, Alafuzoff I, Kristensson K, Dallner G. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J Neurochem 1992; 59: 1646-1653.
124. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BC, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001; 3: 905-912.
125. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexanoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA 2005; 102: 10858-10863.
126. Kim HY, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000; 275: 35215-35223.
127. Kim HY, Akbar M, Kim YS. Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 165-172.
128. Cao D, Kevala K, Kim J, Moon HS, Jun SB, Lovinger D, Kim HY. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem 2009; 111: 510-521.
129. Miñano A, Xifró X, Pérez V, Barneda-Zahonero B, Saura CA, Rodríguez-Alvarez J. Estradiol facilitates neurite maintenance by a Src/Ras/ERK signalling pathway. Mol Cell Neurosci 2008; 39: 143-151.
130. Robson LG, Dyall S, Sidloff D, Michael-Titus AT. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurons throughout development and in aged animals. Neurobiol Aging 2010; 31: 678-687.
131. Arevalo MA, Ruiz-Palmero I, Scerbo MJ, Acaz-Fonseca E, Cambiasso MJ, Garcia-Segura LM. Molecular mechanisms involved in the regulation of neuritogenesis by estradiol: recent advances. J Steroid Biochem Mol Biol 2012; 131: 52-56.
132. Nathan BP, Barsukova AG, Shen F, McAsey M, Struble RG. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 2004; 145: 3065-3073.
133. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
134. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein ε4 allele. J Neurosci 1997; 17: 516-529.
135. Alessandrini A, Facci P. Unraveling lipid/protein interaction in model lipid bilayers by atomic force microscopy. J Mol Recognit 2011; 24: 387-396.
136. Extier A, Perruchot MH, Baudry C, Guesnet P, Lavialle M, Alessandri JM. Differential effects of steroids on the synthesis of polyunsaturated fatty acids by human neuroblastoma cells. Neurochem Int 2009; 55: 295-301.
137. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 2007; 32: 619-634.
138. Wood WG, Schroeder F, Igbavboa U, Avdulov NA, Chochina SV. Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol Aging 2002; 23: 685-694.
139. Morissette M, Al Sweidi S, Callier S, Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 2008; 290: 60-69.
140. Marin R, Guerra B, Alonso R, Ramírez CM, Díaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res 2005; 2: 287-301.
141. Honda K, Sawada H, Kihara T, Urushitani M, Nakamizo T, Akaike A, Shimohama S. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons. J Neurosci Res 2000; 60: 321-327.
142. Arevalo MA, Ruiz-Palmero I, Scerbo MJ, Acaz-Fonseca E, Cambiasso MJ, Garcia-Segura LM. Molecular mechanisms involved in the regulation of neuritogenesis by estradiol: Recent advances. J Steroid Biochem Mol Biol 2012; 131: 52-56.
143. Zhang L, Rubinow DR, Xaing G, Li BS, Chang YH, Maric D, Barker JL, Ma W. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. Neuroreport 2001; 12: 1919-1923.
144. Goodenough S, Schäffer M, Behl C. Estrogen-induced cell signaling in a cellular model of Alzheimer's disease. J Steroid Biochem Mol Biol 2003; 84: 301-305.
145. Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C. Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes. Neuroscience 2005; 132: 581-589.
146. Harms C, Lautenschlager M, Bergk A, Katrchanov J, Freyer D, Kapinya K, Herwig U, Megow D, Dirnagl U, Weber JR, Hörtnagl H. Differential mechanisms of neuroprotection by 17 b-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 2001; 21: 2600-2609.
147. Honda K, Shimohama S, Sawada H, Kihara T, Nakamizo T, Shibasaki H, Akaike A. Nongenomic antiapoptotic signal transduction by estrogen in cultured cortical neurons. J Neurosci Res 2001; 64: 66-475.
148. Yao J, Brinton RD. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol 2012; 64: 327-71.
149. Matsuzaki H, Tamatani M, Mitsuda N, Namikawa K, Kiyama H, Miyake S, Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 1999; 73: 2037-2046.
150. D'Astous M, Mendez P, Morissette M, Garcia-Segura LM, Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice. Mol Pharmacol 2006; 69: 1492-1498.
151. Chen Y, Su Y, Run X, Sun Z, Wang T, Sun S, Liang Z. Pretreatment of PC12 Cells with 17β-estradiol Prevents Aβ-Induced Down-Regulation of CREB Phosphorylation and Prolongs Inhibition of GSK-3β. J Mol Neurosci 2013; 50: 394-401.
152. Nakao N. An increase in intracellular levels of cyclic AMP produces trophic effects on striatal neurons developing in culture. Neuroscience 1998; 82: 1009-1020.
153. Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides 2002; 23: 1471-1478.
154. Lahiri DK, Ge YW. Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein. Ann N Y Acad Sci 2004; 1030: 310-316.
155. Liu SB, Zhang N, Guo YY, Zhao R, Shi TY, Feng SF, Wang SQ, Yang Q, Li XQ, Wu YM, Ma L, Hou Y, Xiong LZ, Zhang W, Zhao MG. G protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. J Neurosci 2012; 32: 4887-4900.